Drug intelligence / Profile preview

Gan-Lu-Yin

Development stage
Phase 2
Lead developer
Jilin Aodong Pharmaceutical Group
Modality
Implantable Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
Administration
Oral
01

Overview

Gan-Lu-Yin is a traditional Chinese herbal formula composed of multiple herbs and used primarily for its anti-inflammatory and detoxifying properties. It is indicated for oral inflammatory conditions such as periodontitis, stomatitis, glossodynia (burning mouth syndrome), chronic pharyngitis, gingivitis, mouth ulcers, sore throat, gum atrophy and swelling. The formula is also used in modern practice as an adjunct therapy in cancer care (notably liver cancer and oral cancer) due to proposed anti-angiogenic effects that may inhibit tumor growth. Additionally, it has been studied for use in autoimmune diseases such as Sjögren’s syndrome and lupus. Mechanistically, Gan-Lu-Yin acts by reducing pro-inflammatory cytokines including IL-1β, IL-6 and TNF-α; inhibiting COX-2 expression; suppressing NF-κB signaling; decreasing osteoclast differentiation to reduce bone resorption; exerting broad-spectrum bacteriostatic effects against pathogens involved in oral disease; modulating immunity via components like Dendrobium officinale polysaccharide. Its ingredients include Radix Rehmanniae praeparata (shu di huang), Radix Ophiopogonis (mai men dong), Fructus Aurantii (zhi ke), Radix Glycyrrhizae praeparata cum melle (zhi gan cao), Herba Artemisiae capillaris (yin chen hao), Folium Eriobotryae (pi pa ye), Herba Dendrobii fimbriati (shi hu), Radix Scutellariae baicalensis (huang qin), Radix Rehmanniae glutinosae recens/sheng di huang) and Radix Asparagi cochinchinensis/tian men dong[2][3][4][5][6].

Brand names
Gan Lu YinSweet Combination
Other names
甘露飲Kanro In (Japanese)Sweet Dew Drink
02

Targets

IL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))IL1B (Interleukin-1 beta)

Beyond the preview

Go deeper on Gan-Lu-Yin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gan-Lu-Yin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call